beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis
- PMID: 15483086
- DOI: 10.1210/jc.2004-1133
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis
Abstract
The nature of the progressive beta-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI] </= 25 kg/m(2)), 42 obese NGT, 22 BMI-matched impaired glucose tolerance [IGT], and 105 BMI-matched T2DM]. Main determinants of beta-cell function on the oral glucose tolerance test were derived from a mathematical model featuring the following: 1) glucose concentration-insulin secretion dose response (glucose sensitivity), 2) a secretion component proportional to the derivative of plasma glucose concentration (rate sensitivity); and 3) a potentiation factor. When NGT and T2DM were subgrouped by 2-h plasma glucose concentrations, insulin secretion rate revealed an inverted U-shaped pattern, rising through NGT up to IGT and falling off thereafter. In contrast, beta-cell glucose sensitivity dropped in a monophasic, curvilinear fashion throughout the range of 2-h plasma glucose. Within the NGT range (2-h glucose of 4.1-7.7 mmol/liter), beta-cell glucose sensitivity declined by 50-70% (P < 0.02). Insulin sensitivity decreased sharply in the transition from lean to obese NGT and then declined further in IGT and mild T2DM to level off in the higher three quartiles of diabetic hyperglycemia. In T2DM, defective beta-cell potentiation and rate sensitivity also emerged (P </= 0.05). In the whole data set, insulin sensitivity and the dynamic parameters of beta-cell function explained 89% of the variability of 2-h plasma glucose levels. The following conclusions were reached: 1) beta-cell glucose sensitivity falls already within the NGT range in association with rising 2-h plasma glucose concentrations, although absolute insulin secretion rates increase; and 2) throughout the glucose tolerance range, dynamic parameters of beta-cell function (glucose sensitivity, rate sensitivity, and potentiation) and insulin sensitivity are independent determinants of 2-h plasma glucose levels.
Similar articles
-
Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.J Clin Endocrinol Metab. 2013 May;98(5):2100-5. doi: 10.1210/jc.2012-3971. Epub 2013 Mar 28. J Clin Endocrinol Metab. 2013. PMID: 23539736 Clinical Trial.
-
Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans.Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E758-64. doi: 10.1152/ajpendo.90737.2008. Epub 2009 Feb 3. Am J Physiol Endocrinol Metab. 2009. PMID: 19190263
-
[Insulin secretion and insulin sensitivity in 1193 inpatients with essential hypertension].Zhonghua Nei Ke Za Zhi. 2004 Oct;43(10):735-9. Zhonghua Nei Ke Za Zhi. 2004. PMID: 15631823 Chinese.
-
Clinical measures of islet function: usefulness to characterize defects in diabetes.Curr Diabetes Rev. 2008 May;4(2):129-45. doi: 10.2174/157339908784220714. Curr Diabetes Rev. 2008. PMID: 18473760 Review.
-
In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance.Diabetes Care. 1996 Mar;19(3):278-86. doi: 10.2337/diacare.19.3.278. Diabetes Care. 1996. PMID: 8742583 Review.
Cited by
-
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.Diabetes. 2013 Nov;62(11):3920-6. doi: 10.2337/db13-0265. Epub 2013 Jul 17. Diabetes. 2013. PMID: 23863810 Free PMC article. Clinical Trial.
-
Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity.J Diabetes Metab. 2016 Apr;7(4):664. doi: 10.4172/2155-6156.1000664. Epub 2016 Apr 28. J Diabetes Metab. 2016. PMID: 27274905 Free PMC article.
-
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0. Epub 2012 Apr 20. Diabetologia. 2012. PMID: 22526604 No abstract available.
-
Dapagliflozin lowers plasma glucose concentration and improves β-cell function.J Clin Endocrinol Metab. 2015 May;100(5):1927-32. doi: 10.1210/jc.2014-3472. Epub 2015 Feb 24. J Clin Endocrinol Metab. 2015. PMID: 25710563 Free PMC article. Clinical Trial.
-
Early insulin secretory dysfunction in korean prediabetic subjects: should we change the criteria for "prediabetes?".Korean Diabetes J. 2010 Jun;34(3):154-6. doi: 10.4093/kdj.2010.34.3.154. Epub 2010 Jun 30. Korean Diabetes J. 2010. PMID: 20617075 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical